Skip to main content
OpenTrials
Completed

NCT Number: NCT05604482

CXCR4-PET/CT for Diagnosing Giant Cell Arteritis

Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy. For large-vessel GCA (LV-GCA) involving the aorta and its branches, FDG-PET/CT is the standard in imaging for diagnosis and is recommended by the guidelines. However, this only indirectly visualizes inflammation through vessel wall uptake of glucose. A new PET tracer, 68Ga-pentixafor, is used to visualize the chemokine receptor CXCR4. This receptor is expressed by cells of the immune system. In the context of inflammatory processes, upregulation of CXCL12, the ligand of CXCR4, occurs in affected tissues. The chemotactic effect of this ligand leads to the immigration of CXCR4-positive inflammatory cells into the inflamed area, which can be visualized by PET using the CXCR4-specific tracer 68Ga-Pentixafor. The value of CXCR4-PET should therefore be tested in the context of LV-GCA. This study tests the benefit of CXCR4 in therapy-naïve patients with suspected LV-GCA. For this purpose, patients will receive a FDG-PET and a CXCR4-PET for direct comparison. This is an imaging-only study. Therapy will not be affected by the study. The study is single-arm and not blinded.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Departement of Internal Medicine II, Rheumatology/Clinical Immunology

Würzburg, Bavaria, 97074, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New diagnosis of GCA within 5 days of diagnosis or initiation or intensification of therapy.
  • Evidence of inflammatory activity based on clinical parameters, elevated serologic markers of inflammation (CRP > 1.0 mg/dl), or a positive imaging finding on vasculitis MRI, CCDS, or FDG-PET/CT
  • Ability of the patient to provide information
  • Exclusion of contraindications for the performance of a PET/CT examination (see below)

Exclusion criteria

  • Contraindications for the performance of a PET CT examination
  • Pregnancy
  • Allergies
  • Lack of capacity of the patient to give informed consent

Treatment and study plan

CXCR4-PET

Diagnostic Test

New imaging modality using CXCR4 for imaging in GCA

Primary outcomes

  1. Maximum measurable tracer activity on 68Ga-Pentixafor PET/CT in the area of blood vessels in active GCA

    Time frame: 2 years

    detection of maximum measurable tracer activity on 68Ga-Pentixafor PET/CT in the area of blood vessels after a maximum of 5 days after diagnosis or when acute inflammatory activity of GCA is detected in terms of recurrence.

Secondary outcomes

  1. Correlation with clinical parameters

    Time frame: 2 years

    Correlation of the measured tracer activity with clinically and laboratory-chemically available parameters that are collected in clinical routine. These include CRP, peripheral blood leukocyte count, calprotectin, serum amyloid A, haptoglobin and Lactate dehydrogenase and their respective progression.

  2. Correlation with blood leukocyte count

    Time frame: 2 years

    Correlation of tracer uptake on imaging with CXCR4-positive peripheral blood leukocyte count.

  3. Comparison to other imaging modalities

    Time frame: 2 years

    Comparison with imaging findings from vasculitis MRI imaging implemented in standard clinical practice, duplex sonography (CCDS), and, if performed as part of routine clinical practice, FDG PET/CT data.

Sponsors and collaborators

Lead sponsor

Matthias Fröhlich

Other

Registry information

Official study title

Detection of Disease Activity in Giant Cell Arteritis Using CXCR4-PET/CT

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Nov 3, 2022
Registry last updated
Dec 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.